CD274 and non-small cell lung carcinoma: Similarly, PEARLS/Keynote 091 was a phase III randomized trial evaluating one year of adjuvant pembrolizumab every three weeks in patients with resected stage IB (T ≥ 4 cm)—IIIA NSCLC (AJCC 7th edition) and any PD-L1 expression [23].